The fiscal year 2020 (FY2020) Inpatient Prospective Payment Systems (IPPS) proposed rule notably includes approximately 1500 complications or comorbidities (CC)/major complications or comorbidities (MCC) designation changes and 324 changes to International Classification of Diseases, Tenth Revision, Clinical Modification codes, along with several other updates. The designation changes are an effort to respond to the notion that the CC/MCC assignment are no longer appropriate as conditions and factors have shifted.
In April, CMS issued the fiscal year (FY) 2020 Inpatient Prospective Payment Systems (IPPS) proposed rule. The proposed rule notably includes approximately 1500 complications or comorbidities (CC)/major complications or comorbidities (MCC) designation changes and 324 changes to International Classification of Diseases, Tenth Revision, Clinical Modification codes, along with several other updates. The designation changes are an effort to respond to the notion that the CC/MCC assignment are no longer appropriate as conditions and factors have shifted.
From a clinical documentation improvement (CDI) perspective, hospitals that focus on CC/MCC designation alone could see effects on their quality ratings if these conditions are not fully evaluated. Some examples of the changes to CC/MCC designations are listed below. Several of the changes fall into chronic conditions that are considered significant by CMS and are areas that quality, as well as clinical documentation integrity programs, often focus their work. These areas include:
Impacts on Hospital Reimbursements
The proposed changes will greatly impact the reimbursement of hospitals and other facilities across the board. The resources required for treatment of these conditions, many of which are no longer considered MCC/CCs, will be a financial burden due to the proposed IPPS rule. More specifically, the changes infer that patients with these disease burdens and conditions do not require as many resources as patients without the condition. In areas such as obesity/malnutrition, heart failure, and chronic kidney disease, it is difficult to agree that these would not require additional resources such as labs, pain management, intakes and outputs, additional imaging, daily weights, and, oftentimes, a higher level of nursing care in general.
Regarding the downgrade of the secondary diagnoses of cancer, the rationale given to downgrade was stated that because it is not the condition that caused the patients admission to the hospital, it does not significantly impact resource use. As in the conditions discussed above, it is difficult to agree that a secondary diagnosis of cancer may not require pain control, lab monitoring, follow-up imaging, or consideration for further complications. Also, if a patient is undergoing active chemotherapy for a secondary diagnosis of cancer, there is always potential for further evaluation, monitoring or treatment.
Conversely, there are proposed changes to CC/MCC designations that are positive and will more accurately reflect the overall patient condition. Some of these include:
CMS has sought public comment on the proposed rule. To view all submitted thoughts and comments, visit https://www.regulations.gov/document?D=CMS-2019-0073-0003. If finalized, proposed changes would affect discharges occurring on or after October 1, 2019.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More